Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide
Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide
复制标题
水飞蓟宾抑制人胰岛淀粉样多肽的毒性聚集
DOI：
10.1016/j.bbrc.2012.02.042
复制
发表时间：
2012-03-16
影响因子：
3.1
通讯作者：
Huang, Kun
中科院分区：
文献类型：
--
作者：
Cheng, Biao;Gong, Hao;Huang, Kun
在2型糖尿病（T2DM）中，错误折叠的人胰岛淀粉样多肽（hIAPP）在胰岛中形成淀粉样沉积物。这些淀粉样蛋白沉积物导致T2DM患者的β细胞功能障碍和β细胞质量损失。抑制hIAPP纤维化已被认为是T2DM的潜在治疗方法。水飞蓟宾是从水飞蓟中提取的一种主要活性黄酮类化合物，在亚洲和欧洲已被用于治疗糖尿病数百年，其机制尚不清楚。在这项研究中，我们测试了水飞蓟宾是否对hIAPP的淀粉样变性有任何影响。我们的研究结果提供了第一个证据表明，水飞蓟宾通过抑制hIAPP的毒性寡聚化来抑制hIAPP的纤维化，并增强胰腺β细胞的活力，因此水飞蓟宾可能作为T2DM的潜在治疗剂。(C)2012 Elsevier Inc. All rights reserved.
In type 2 diabetes mellitus (T2DM), misfolded human islet amyloid polypeptide (hIAPP) forms amyloid deposits in pancreatic islets. These amyloid deposits contribute to the dysfunction of beta-cells and the loss of beta-cell mass in T2DM patients. Inhibition of hIAPP fibrillization has been regarded as a potential therapeutic approach for T2DM. Silibinin, a major active flavonoid extracted from herb milk thistle (Silybum marianum), has been used for centuries to treat diabetes in Asia and Europe with unclear mechanisms. In this study, we tested whether silibinin has any effect on the amyloidogenicity of hIAPP. Our results provide first evidence that silibinin inhibits hIAPP fibrillization via suppressing the toxic oligomerization of hIAPP and enhances the viability of pancreatic beta-cells, therefore silibinin may serve as a potential therapeutic agent for T2DM. (C) 2012 Elsevier Inc. All rights reserved.